Study of Dasatinib and All-Trans Retinoic Acid for Relapsed/Refractory and/or Elderly Patients With Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome

Model scores of the 29,894 trials active now.

Model score 24% for any early termination, 18% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 23% of the time (1,629 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2016-02-29. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: amlleukemiacellcancerrisk
  Phrases that lowered it: openlabeldoseproductsdrug
• Phase: 1 (lowers risk) · Design
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Disease area, cancer: Yes (raises risk) · Disease area
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor's past termination rate: 8.1% (raises risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 89 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Drug's FAERS reports with a death: 23.3% (raises risk) · Drug's FDA history
• Sponsor's past trials: 209 (lowers risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Drug's FAERS reports marked serious: 89.7% (raises risk) · Drug's FDA history
• Keywords listed: 9 (lowers risk) · Design
• Maximum age: not given (raises risk) · Who can join
• Responsible party: sponsor (lowers risk) · Design
• Collaborators: 0 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia NCT00940524 · started 2009 · scored riskier than 45% of active trials completed
• Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia NCT01441882 · started 2011 · scored riskier than 99% of active trials completed
• Dasatinib in Combination With Melphalan and Prednisone to Treat Relapsed and Refractory Multiple Myeloma Patients NCT01116128 · started 2008 · scored riskier than 91% of active trials terminated
• A Study of Dasatinib and Rituximab for Relapsed/Refractory Chronic Lymphocytic Leukemia NCT00949988 · started 2009 · scored riskier than 95% of active trials terminated
• Dasatinib In Combination With Weekly Paclitaxel For Patients With Metastatic Breast Carcinoma CA 180 194 NCT00820170 · started 2009 · scored riskier than 66% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.